Valneva Reports Five-Year Antibody Persistence Data of Single-Dose Chikungunya Vaccine Ixchiq

Shots: Valneva has reported 5yr antibody persistence data from the VLA1553-303 trial of its single-dose chikungunya vaccine, Ixchiq, supported by CEPI & the EU’s Horizon Europe program Among 221 evaluable healthy adults at Yr5, 94% maintained neutralizing antibody titers above the seroresponse threshold, with comparable GMTs & seroresponse rates in adults aged ≥65yrs & 18-64yrs, consistent with earlier persistence results Participants will be followed for up to 10yrs; Valneva also supported Brazil’s Pilot Vaccination Strategy (Feb-Oct 2026) with Instituto Butantan, which vaccinated ~80,000 adults aged 18-59yrs & underpins ongoing post-marketing studies Ref: GlobeNewswire  |   Image: Valneva  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Valneva Reports Five-Year Antibody Persistence Data of Single-Dose Chikungunya Vaccine Ixchiq appeared first on PharmaShots.